The UK Government has launched a research project into understanding the causes of...
Twitter round-up: Neurology tweets – David Perlmutter’s tweet on meditation most popular in December 2019
Pharmaceutical Technology lists ten of the most popular tweets on neurology in December 2019, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked by GlobalData’s Influencer Platform, which is based on a scientific process that works on pre-defined parameters. Influencers are selected after a deep analysis of the influencer’s relevance, network strength, engagement, and leading discussions on new and emerging trends.
Can controlled substances become the new standard of care for psychiatric disorders?
First-line therapies such as Zoloft (sertraline hydrochloride) and benzodiazepines such as diazepam also come with boxed warnings due to the increased risk of suicidal tendencies.
UK Government invests £35m into researching adolescent mental health
The UK Government has launched a research project into understanding the causes of mental health problems in teenagers and young adults, including the genetics and societal influences underpinning why some people are more susceptible than others.
ViiV unveils emotional challenges related to HIV ART treatment
GSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency virus (HIV) antiretroviral therapy (ART) on people living with the condition.
Takeda and Lundbeck’s Trintellix approved in Japan for depression
Takeda has announced that its drug Trintellix (vortioxetine) has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of depression and depressed state.
Can sleep disruptions lead to Alzheimer’s disease?
An October 2018 study published in the European Journal of Epidemiology by Bokenberger and colleagues found that previous history of shift work and working night shifts were both associated with an approximately 30% increase in dementia incidence.
Janssen’s esketamine reduces symptoms in suicidal depression
Johnson & Johnson subsidiary Janssen has announced its esketamine nasal spray reduced depressive symptoms in adult major depressive disorder patients with suicidal ideation with intent when combined with the standard of care.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.